Johnson & Johnson announces results from Phase 2b ANTHEM-UC study of icotrokinra

Johnson & Johnson announced Week 28 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis. These results underscore the potential of icotrokinra to deliver a combination of therapeutic benefit and a favorable safety profile with once-daily oral dosing and will be featured among Johnson & Johnson’s 23 accepted abstracts at the 2025 American College of Gastroenterology Annual Scientific Meeting. At Week 28, icotrokinra demonstrated sustained and clinically meaningful results, with all doses (100 mg, 200 mg and 400 mg) showing higher rates of clinical responsea, clinical remissionb, endoscopic improvementc and histologic-endoscopic mucosal improvement at Week 28 compared to placebo. These outcomes build on Week 12 data recently presented at United European Gastroenterology Week 2025 where all doses of icotrokinra demonstrated superiority to placebo for the primary endpoint of clinical response.